Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Artigo em Inglês | MEDLINE | ID: mdl-32431778

RESUMO

Inclusivity in STEM requires practices that include transforming the culture in a classroom. This can be done not only by placing value on diversity but also by providing an engaging student experience, instilling a sense of belonging, and encouraging students at all levels to use a critical lens to solve problems. As a way to develop an inclusive science curriculum for students in a community that is among the poorest in New York state, local STEM organization Rise High Inc. partners with experts in STEM fields, K-12 educators, mentors, and community organizations to create sustainable low-cost, high-quality, engaging, and relevant content that sparks curiosity and exploration for this underserved community. The educators and mentors also have a unique opportunity to develop self-awareness about their own pathways and how they can use their experiences to enrich the classroom. An exemplary case is this highly interactive two-part instructional module in Microbiology and Immunology, which targets 8th graders and was designed in partnership with a local expert in these fields. This module offers creative means to learn and apply knowledge in realistic ways, while using easy-to-access materials in classrooms.

2.
Mol Imaging Biol ; 10(4): 177-81, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18481153

RESUMO

PURPOSE: In this study, we introduce a methodology for preparing 18F-labeled Affibody protein, specifically 18F-Anti-HER2 dimeric Affibody (14 kDa), for in vivo imaging of HER2neu with positron emission tomography (PET). PROCEDURES: We have used 4-[18F]fluorobenzaldehyde as a synthon to prepare 18F-Anti-HER2 Affibody. Aminooxy-functionalized Affibody (Anti-HER2-ONH2) was incubated with 4-[18F]fluorobenzaldehyde in ammonium acetate buffer at pH 4 in the presence of methanol at 70 degrees C for 15 min. The resulting 18F-labeled Affibody molecule was evaluated as a PET probe in xenograft models expressing HER2. RESULTS: We have successfully prepared 18F-Anti-HER2 dimeric Affibody (14 kDa), N-(4-[18F]fluorobenzylidine)oxime-Anti-HER2 Affibody, [18F]FBO-Anti-HER2, in 26-30% radiochemical yields (decay corrected). High-contrast small-animal PET images with relatively moderate tumor uptake (1.79 +/- 0.40% ID/g) were observed for the 18F-Anti-HER2 Affibody. CONCLUSION: Site-specific 18F-labeled Affibody against HER2 has been synthesized via chemoselective oxime formation between an aminooxy-functionalized Affibody and 18F-fluorobenzaldehyde. The results have implications for radiolabeling of other affibodies and macromolecules and should also be important for advancing Affibody imaging with PET.


Assuntos
Benzaldeídos/química , Marcação por Isótopo , Oximas/química , Proteínas/metabolismo , Compostos Radiofarmacêuticos , Animais , Linhagem Celular Tumoral , Dimerização , Estudos de Viabilidade , Feminino , Radioisótopos de Flúor , Humanos , Camundongos , Camundongos Nus , Estrutura Molecular , Peso Molecular , Oligopeptídeos/química , Oligopeptídeos/metabolismo , Tomografia por Emissão de Pósitrons/métodos , Ligação Proteica , Proteínas/química , Proteínas/genética , Radioquímica , Compostos Radiofarmacêuticos/síntese química , Compostos Radiofarmacêuticos/farmacocinética , Receptor ErbB-2/química , Receptor ErbB-2/genética , Receptor ErbB-2/metabolismo , Proteínas Recombinantes de Fusão/química , Proteínas Recombinantes de Fusão/metabolismo , Sensibilidade e Especificidade , Ressonância de Plasmônio de Superfície , Distribuição Tecidual , Ensaios Antitumorais Modelo de Xenoenxerto
3.
Bioconjug Chem ; 13(3): 443-52, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12009932

RESUMO

Attachment of drugs to high molecular weight polymers can significantly improve both tumor targeting and therapeutic efficacy due to the enhanced permeability and retention effect observed in tumor tissue. However, the commercial availability of well-defined water-soluble polymeric systems with narrow polydispersities that are biocompatible, nontoxic, and nonimmunogenic is rather limited. To address this need, we have investigated dendritic polymers as promising scaffolds for the preparation of new soluble polymeric drug carriers due to their well-defined molecular architecture and their multiplicity of surface sites. Herein we show the design and synthesis of dendritic polyester systems based on the monomer unit 2,2-bis(hydroxymethyl)propanoic acid as a possible versatile drug carrier. The potent anticancer drug doxorubicin was attached via a pH-sensitive linkage to one of the carriers presented, demonstrating the feasibility of using these polyester dendritic structures to prepare a viable polymer-drug conjugate.


Assuntos
Antibióticos Antineoplásicos/administração & dosagem , Doxorrubicina/administração & dosagem , Sistemas de Liberação de Medicamentos , Poliésteres/síntese química , Propionatos/síntese química , Portadores de Fármacos , Desenho de Fármacos , Concentração de Íons de Hidrogênio , Hidroxiácidos , Poliésteres/química
4.
Bioconjug Chem ; 13(3): 453-61, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12009933

RESUMO

High molecular weight polymers (> 20 000 Da) have been widely used as soluble drug carriers to improve drug targeting and therapeutic efficacy. Dendritic polymers are exceptional candidates for the preparation of near monodisperse drug carriers due to their well-defined structure, multivalency, and flexibility for tailored functionalization. We evaluated various dendritic architectures composed of a polyester dendritic scaffold based on the monomer unit 2,2-bis(hydroxymethyl)propanoic acid for their suitability as drug carriers both in vitro and in vivo. These systems are both water soluble and nontoxic. In addition, the potent anticancer drug, doxorubicin, was covalently bound via a hydrazone linkage to a high molecular weight 3-arm poly(ethylene oxide)-dendrimer hybrid. Drug release was a function of pH, and the release rate was more rapid at pH < 6. The cytotoxicity of the DOX-polymer conjugate measured on multiple cancer lines in vitro was reduced but not eliminated, indicating that some active doxorubicin was released from the drug polymer conjugate under physiological conditions. Furthermore, biodistribution experiments show little accumulation of the DOX-polymer conjugate in vital organs, and the serum half-life of doxorubicin attached to an appropriate high molecular weight polymer has been significantly increased when compared to the free drug. Thus, this new macromolecular system exhibits promising characteristics for the development of new polymeric drug carriers.


Assuntos
Antibióticos Antineoplásicos/administração & dosagem , Doxorrubicina/administração & dosagem , Portadores de Fármacos/síntese química , Poliésteres/síntese química , Polímeros/síntese química , Animais , Antibióticos Antineoplásicos/farmacocinética , Antibióticos Antineoplásicos/uso terapêutico , Divisão Celular/efeitos dos fármacos , Células Cultivadas , Doxorrubicina/farmacocinética , Doxorrubicina/uso terapêutico , Portadores de Fármacos/química , Portadores de Fármacos/farmacologia , Sistemas de Liberação de Medicamentos , Desenho de Fármacos , Ensaios de Seleção de Medicamentos Antitumorais , Feminino , Concentração de Íons de Hidrogênio , Taxa de Depuração Metabólica , Camundongos , Microscopia Confocal , Microscopia de Fluorescência , Oxirredução , Poliésteres/química , Poliésteres/farmacologia , Polímeros/química , Polímeros/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA